Pembrolizumab ELISA Kit (ab237652)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 30 ng/ml - 1000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Quantitative
- Reacts with: Human
Overview
-
Product name
Pembrolizumab ELISA Kit -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall < 30% Inter-assay Sample n Mean SD CV% Overall < 30% -
Sample type
Serum, Plasma -
Assay type
Quantitative -
Sensitivity
30 ng/ml -
Range
30 ng/ml - 1000 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Note: Pembrolizumab ELISA kit ab237652 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Pembrolizumab in the sample or standard. Results of samples can be determined directly using the standard curve.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called E4383 BioSim™ Pembrolizumab (Human) ELISA Kit. E4383-100 is the same size as the 96 test size of ab237652.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests 96 tests Assay Buffer 2 x 50ml 2 x 50ml HRP-conjugate Probe 1 x 12ml 1 x 12ml Micro ELISA Plate 1 unit 1 unit Pembrolizumab Standard S1 1 x 0.3ml 1 x 0.3ml Pembrolizumab Standard S2 1 x 0.3ml 1 x 0.3ml Pembrolizumab Standard S3 1 x 0.3ml 1 x 0.3ml Pembrolizumab Standard S4 1 x 0.3ml 1 x 0.3ml Pembrolizumab Standard S5 1 x 0.3ml 1 x 0.3ml Pembrolizumab Standard S6 1 x 0.3ml 1 x 0.3ml Pembrolizumab Standard S7 1 x 0.3ml 1 x 0.3ml Plate sealers 2 units 2 units Stop Solution 1 x 12ml 1 x 12ml TMB substrate 1 x 12ml 1 x 12ml Wash Buffer (10X) 1 x 50ml 1 x 50ml -
Relevance
Pembrolizumab is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells.
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab237652 has been referenced in 1 publication.
- Gauckler P et al. Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma-A case report. J Clin Apher 35:227-230 (2020). PubMed: 32142176